Malignant insulinoma: Spectrum of unusual clinical features

Cancer

Volumn 104, Issue 2, 2005, Pages 264-272

  Hirshberg, Boaz ^a,d   Cochran, Craig ^a   Skarulis, Monica C ^a   Libutti, Steven K ^b   Alexander, H Richard ^b   Wood, Bradford J ^c   Chang, Richard ^c   Kleiner, David E ^c   Gorden, Phillip ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d PFIZER INC   (United States)

Author keywords

Beta cell tumor; Endocrine; Insulinoma; Neoplasia

Indexed keywords

ALPHA FETOPROTEIN; DIAZOXIDE; DOXORUBICIN; GLUCOSE; STREPTOZOCIN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INSULINOMA; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS BIOPSY; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; FEMALE; HUMANS; HYPOGLYCEMIA; INSULINOMA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS;

EID: 22244456359     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21179     Document Type: Article

References (39)

1. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001; 81:527-542.
2. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases; outcomes of an aggressive approach. Surgery. 2002;132:976-982.
3. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991; 66:711-719.
4. Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222-3226.
5. Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not necessary. J Am Coll Surg. 1999;189:368-373.
6. Danforth DN Jr., Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery. 1984;96:1027-1037.
7. Gorden P, Skarulis MC, Roach P, et al. Plasma proinsulin-like component in insulinoma: a 25-year experience. J Clin Endocrinol Metab. 1995;80:2884-2887.
8. Bushnell D, O'Dorisio T, Menda Y, et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med. 2003;44:1556-1560.
9. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 FASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
10. Hesdorffer CS, Stoopler M, Javitch J. Aggressive insulinoma with bone metastases. Am J Clin Oncol. 1989;12:498-501.
11. Grama D, Erlksson B, Martensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg. 1992; 16:632-639.
12. Lee CH, Lee G, Kim DH, et al. A large malignant insulinoma: case report with endosonographic, immunohistochemical and ultrastructural features. Korean J Intern Med. 2003;18: 45-49.
13. Lam K, Lo C, Wat M, Fan ST. Malignant insulinoma with hepatoid differentiation: a unique case with alpha-fetoprotein production. Endocr Pathol. 2001;12:351-354.
14. Shimoike T, Goto M, Nakano I, et al. Acinar-islet cell carcinoma presenting as insulinoma. J Gastroenterol. 1997;32: 830-835.
15. Graeme-Cook F, Nardi G, Compton CC. Immunocytochemical staining for human chorionic gonadotropin subunits does not predict malignancy in insulinomas. Am J Clin Pathol. 1990;93:273-276.
16. Kobayashi M, Kawa S, Kobayashi M, Imai Y, Sodeyama T, Kiyosawa K. Malignant insulinoma presenting as a non-functioning metastatic liver tumor 14 years after resection of the primary tumor. J Gastroenterol. 1998;33:891-894.
17. Moscetti L, Saltarelli R, Giuliani R, Fornarini G, Bezzi M, Cortesi E. Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature. Tumori. 2000;86:475-479.
18. Sata N, Kimura W, Kanazawa T, Muto T. Malignant insulinoma causing liver metastasis 8 years after the initial surgery: report of a case. Surg Today. 1995;25:640-642.
19. Scott A, Hinwood D, Donnelly R. Radio-frequency ablation for symptom control in a patient with metastatic pancreatic insulinoma. Clin Endocrinol. 2002;56:557-559.
20. Arioglu E, Gottlieb NA, Koch CA, Doppman JL, Grey NJ, Gorden P. Natural history of a proinsulin-secreting insulinoma: from symptomatic hypoglycemia to clinical diabetes. J Clin Endocrinol Metab. 2000;85:3628-3630.
21. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73: 640-641.
22. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol. 2000;12:151-157.
23. Nesovic M, Ciric J, Radojkovic S, Zarkovic M, Durovic M. Improvement of metastatic endocrine tumors of the pancreas by hepatic artery chemoembolization. J Endocrinol Invest. 1992;15:543-547.
24. Schulz B, Hehmke B, Zander E, Ziegler B. Autoimmune reactions in a patient with malignant insulinoma treated by multiple low dose streptozotocin. Exp Clin Endocrinol. 1990; 95:77-82.
25. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17:474-478.
26. Longnecker SM. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide. Drug Intell Clin Pharm. 1988;22:136-138.
27. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989;34:28S-39S.
28. Winkelbauer FW, Nierderle B, Graf O, et al. Malignant insulinoma: permanent hepatic artery embolization of liver metastases-preliminary results. Cardiovasc Intervent Radiol. 1995;18:353-359.
29. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397-403.
30. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992;112:1024-1031.
31. Schein PS. Islet cell tumors: current concepts and management. Ann Intern Med. 1973;79:239-257.
32. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with Streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980; 303:1189-1194.
33. Tran TH, Pathak RD, Basa AL. Metastatic insulinoma: case report and review of the literature. South Med J. 2004;97: 199-201.
34. Alberts AS, Falkson G. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide). A case report. S Afr Med J. 1988;74:75-76.
35. Lawrence JM, Smith T, lies D, Reckless JP. Difficult insulinoma. J R Soc Med. 2001;94:349-350.
36. Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110:35-50.
37. D'Arcangues CM, Awoke S, Lawrence GD. Metastatic insulinoma with long survival and glucagonoma syndrome. Ann Intern Med. 1984;100:233-235.
38. Samaan NA, Pham FK, Sellin RV, Fernandez JF, Benjamin RS. Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor. Ann Intern Med. 1990;113:404-406.
39. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123:269-273.